ArticleHealth services research2019
Physician characteristics, industry transfers, and pharmaceutical prescribing: Empirical evidence from medicare and the physician payment sunshine act.
Article in Health services research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Are Financial Payments From the Pharmaceutical Industry Associated With Physician Prescribing? : A Systematic Review.Annals of internal medicine · 2021Pooled it
- Assessing the impact of the Physician Payments Sunshine Act on pharmaceutical companies' payments to physicians.PloS one · 2024Article
- Pharmaceutical industry payments and delivery of non-recommended and low value cancer drugs: population based cohort study.BMJ (Clinical research ed.) · 2023Article
- Pharmaceutical industry payments to NHS trusts in England: A four-year analysis of the Disclosure UK database.PloS one · 2023Article
- Industry Payments to Physicians Are Kickbacks. How Should Stakeholders Respond?Journal of health politics, policy and law · 2022Article
- Associations Between Industry Payments to Physicians for Antiplatelet Drugs and Utilization of Cardiac Procedures and Stents.Journal of general internal medicine · 2022Article
- Article
- Changes in industry marketing payments to physicians during the covid-19 pandemic: quasi experimental, difference-in-difference study.BMJ medicine · 2022Article
- Increasing Financial Payments From Industry to Medical Oncologists in the United States, 2014-2017.Journal of the National Comprehensive Cancer Network : JNCCN · 2021Article
- Article
- Association between physician characteristics and payments from industry in 2015-2017: observational study.BMJ open · 2019Observational
- Physician characteristics, industry transfers, and pharmaceutical prescribing: Empirical evidence from medicare and the physician payment sunshine act.Health services research · 2019Article
- Despise the free lunch.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology AssociationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
objectiveTo evaluate physician characteristics associated with pharmaceutical industry transfers and prescribing behavior after public reporting under the Sunshine Act. DATA SOURCES: 2014-2016 secondary data on industry transfers to physicians from the Open Payments Dataset supplemented with Medicare Part D prescription data, Medicare service data, and practice attributes from the Physician Compare Database. STUDY
designUsing regression analysis with county/physician fixed effects, this study examines characteristics associated with the probability/magnitude of transfers and the association between transfers and prescriptions. DATA COLLECTION: Using an iterative matching approach, this study identifies physicians who delivered outpatient Medicare services in 2014 (n = 409 041) and tracks their annual transfers between 2014 and 2016 (N = 1 227 123) across six transfer categories. In addition, it examines their Medicare Part D prescription behavior between 2014 and 2015 (N = 741 659). PRINCIPAL
findingsIndustry transfers dramatically declined in 2015 and 2016. Transfers are significantly associated with increased prescription costs, branded prescribing, and prescribing for High-Risk Medications (HRMs).
conclusionsIndustry transfers have declined after public reporting. Transfers are associated with higher prescription costs and incidence of HRMs. Future research is needed to determine the causal impact on quality and cost-effectiveness of prescribed medications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.